Predicting pharmacoresistance in pediatric epilepsy.

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations


Approximately 20% of children with epilepsy will be pharmacoresistant. The impact of intractable epilepsy extends far beyond just the seizures to result in intellectual disability, psychiatric comorbidity, physical injury, sudden unexpected death in epilepsy (SUDEP), and poor quality of life. Various predictors of pharmacoresistance have been identified; however, accurate prediction is still challenging. Population-based epidemiologic studies show that the majority of children who develop pharmacoresistance do so relatively early in the course of their epilepsy. However, approximately one third of children who initially appear pharmacoresistant in the first few years after epilepsy onset will ultimately achieve seizure freedom without surgery. The most significant predictor that early pharmacoresistance will not remit is the presence of a neuroimaging abnormality. Such children should be strongly considered for surgical evaluation. Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)19-22
Number of pages4
JournalUnknown Journal
Volume54 Suppl 2
StatePublished - May 2013

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Predicting pharmacoresistance in pediatric epilepsy.'. Together they form a unique fingerprint.

Cite this